Why Immunome Stock Surged Today [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
10 stocks we like better than Immunome › Shares of Immunome (NASDAQ: IMNM) jumped over 15% on Monday after the biotech company announced positive clinical results for varegacestat, an investigational treatment for patients with progressing desmoid tumors. Desmoid tumors can be debilitating and lead to life-threatening organ damage. Each year, 1,000 to 1,650 people are diagnosed with the health condition in the U.S. alone. "Desmoid tumors can have a devastating physical and emotional impact on patients given their unpredictable nature and the limitations of current treatment options," Dr. Mrinal Gounder, the trial's primary investigator, said in a press release. The phase 3 clinical trial met its primary endpoint of improving progression-free survival, with an 84% reduction in the risk of disease progression or death compared to placebo. The trial also met all key secondary endpoints, including reductions in tumor volume and pain intensity. Importantly, Varegacestat was gene
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome (NASDAQ:IMNM) had its price target raised by analysts at Evercore ISI from $18.00 to $40.00. They now have an "outperform" rating on the stock.MarketBeat
- Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application [Yahoo! Finance]Yahoo! Finance
- Immunome (NASDAQ:IMNM) was given a new $40.00 price target on by analysts at Leerink Partners.MarketBeat
- Immunome Announces Proposed Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/15/25 - Form 424B5
- 12/15/25 - Form 8-K
- 11/7/25 - Form SCHEDULE
- IMNM's page on the SEC website